We are live on ! Find out more

Carlsmed

CARL

Market cap $401M

14.69 USD

-0.33

2.2%

At close Updated Nov 3, 1:26 PM EST

1 day

-2.2%

5 days

-7.61%

1 month

-3.99%

3 months

13.61%

6 months

61.61%

Year to date

26.31%

1 year

20.21%

5 years

1.31%

10 years

1.31%

About: Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.

Employees: 127

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.1%

Neutral 92.9%

Negative 0%

Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026

CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.

Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026.

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company's common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company's newly-hired Chief Financial Officer, as a material inducement to his employment.

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Carlsmed Appoints Tony Jarc as Chief Product and AI Officer

CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company's next generation technology platform, surgical UI/UX, and personalized spine surgery procedures.

Carlsmed Appoints Tony Jarc as Chief Product and AI Officer

Carlsmed Appoints Richard Heppenstall as Chief Financial Officer

CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately.

Carlsmed Appoints Richard Heppenstall as Chief Financial Officer

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Carlsmed, Inc. Announces Chief Operating Officer Appointment

CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company's Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturing Technologies. Prior to joining Carlsmed, Jeff held senior leadership positions in operations and technology at SI-BONE, NuVasive, and US Surgical.

Carlsmed, Inc. Announces Chief Operating Officer Appointment

Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform

Carlsmed NASDAQ: CARL outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event.

Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™